Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE (Details 1)

v3.22.1
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2020
USD ($)
Equity_Instrument
$ / shares
Feb. 29, 2020
Debt Instrument [Line Items]      
Interest rate     10.00%
Principal Outstanding $ 22,339 $ 15,294  
Unamortized Discount 4,332 1,720  
Carrying Amount $ 18,007 $ 13,574  
Shares Underlying Notes | Equity_Instrument 10,173,099 3,946,723  
Principal Outstanding, Current $ 800    
Convertible notes payable, Current 10,158    
Principal Outstanding, Non Current 800    
Convertible notes payable, Non-current 3,150 $ 3,150  
2019 Notes payable - related party [Member]      
Debt Instrument [Line Items]      
Principal Outstanding 800 134  
Carrying Amount 800 134  
Principal Outstanding, Current $ 800 $ 134  
2018 Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Interest rate   12.00%  
Term of Notes   2 years  
Conversion Price | $ / shares [1]   $ 10.00  
Principal Outstanding   $ 3,150  
Carrying Amount   $ 3,150  
Shares Underlying Notes | Equity_Instrument   316,723  
2020 Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Interest rate 12.00%    
Term of Notes 3 years    
Conversion Price | $ / shares [1] $ 10.00    
Principal Outstanding $ 3,150    
Carrying Amount $ 3,150    
Shares Underlying Notes | Equity_Instrument 316,756    
2021 Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Interest rate 2.00%    
Term of Notes 3 years    
Conversion Price | $ / shares [2] $ 1.48    
Principal Outstanding $ 14,490    
Unamortized Discount 4,332    
Carrying Amount $ 10,158    
Shares Underlying Notes | Equity_Instrument 9,856,343    
Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Principal Outstanding $ 17,640 $ 3,150  
Unamortized Discount 4,332    
Carrying Amount $ 13,308 $ 3,150  
Shares Underlying Notes | Equity_Instrument 10,173,099 316,723  
Principal Outstanding, Current $ 14,490 $ 3,150  
Unamortized Discount, Current 4,332    
Convertible notes payable, Current $ 10,158 $ 3,150  
Shares Underlying Notes Current | Equity_Instrument 9,856,343 316,723  
Principal Outstanding, Non Current $ 3,150    
Convertible notes payable, Non-current $ 3,150    
Shares Underlying Notes Non Current | Equity_Instrument 316,756    
[1] This note is convertible into EMI Holdings Inc. shares.
[2] The notes are convertible into Emmaus Life Sciences, Inc. shares. Beginning February 28, 2022, the holder is entitled to call for early redemption, only if the Company’s common stock is not approved for listing on the NYSE American, the Nasdaq Capital Market or other Trading Market (as defined in the agreement). As the Company's common stock is not approved for listing, the notes were classified as current.